Top Markets
Coin of the day
ARYx Therapeutics, Inc. ARYx Therapeutics, Inc.

ARYx Therapeutics, Inc.

ARYX
株式のランク #41544
Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc.... Based in Fremont, California, and established in 1997, ARYx Therapeutics, Inc. is dedicated to discovering and advancing innovative treatments, primarily focusing on widespread, chronic conditions addressable with oral medications. The company utilizes its unique RetroMetabolic Drug Design technology to engineer distinctive molecular compounds that maintain the therapeutic effectiveness of their original counterparts. Its clinical development portfolio includes several promising candidates: Tecarfarin (ATI-5923): An oral anticoagulant currently in Phase III clinical trials, aimed at preventing hazardous blood clots in at-risk patients. Budiodarone (ATI-2042): An oral antiarrhythmic agent undergoing Phase IIb development for managing atrial fibrillation, a form of irregular heart rhythm. ATI-7505: An oral prokinetic agent in Phase IIb clinical development, targeting various gastrointestinal issues such as chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease. ATI-9242: An antipsychotic agent progressing through Phase I clinical trials for the treatment of schizophrenia and other psychiatric conditions. Additionally, ARYx Therapeutics is conducting early-stage research on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal ailments.
株価
$0.0005
最終同期: 2026-08-11
時価総額
$16.73K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 ARYx Therapeutics, Inc. (ARYX)

カテゴリー

ARYx Therapeutics, Inc.(ARYX)のP/S比率
2026 時点のP/S比率 TTM: 0
ARYx Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
ARYx Therapeutics, Inc. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。